Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients

Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients.

The analysis, published today in the Journal of the American Medical Association (JAMA), showed that Novocure’s Optune-temozolomide combo extended overall survival and progression-free survival by 37% compared to temozolomide alone.

Get the full story at our sister site, Drug Delivery Business News.

The post Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients appeared first on MassDevice.

from MassDevice http://ift.tt/2BfXt0b